NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
TRDA
Entrada Therapeutics, Inc.
There isn't enough reported data to score TRDA yet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
TRDA Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Strong |
TRDA's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
TRDA PE Valuation
TRDA has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
TRDA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect TRDA's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over TRDA on earnings quality, reporting a profit while its opponent remains loss making.
TRDA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.85 | -$1.36 |
| Q2 2026 | -$3.97 | -$2.19 |
| Q1 2026 | -$4.00 | -594% |
| Q4 2025 | -$3.47 | -282% |
| Q3 2025 | -$2.49 | -251% |
| Q2 2025 | -$1.78 | -159% |
| Q1 2025 | $0.81 | +17% |
| Q4 2024 | $1.91 | +$2.11 |
TRDA lost $3.85 per share over the past year, a bigger loss than the year before.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over TRDA on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over TRDA on profitability, with a higher operating margin.
TRDA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $905K | -44% |
| Q2 2026 | $898K | -54% |
| Q1 2026 | $875K | -96% |
| Q4 2025 | $1.3M | -97% |
| Q3 2025 | $1.6M | -92% |
| Q2 2025 | $2M | -98% |
| Q1 2025 | $20.6M | -65% |
| Q4 2024 | $37.4M | -11% |
TRDA's revenue has slid since its 2024 peak: $905,000 last quarter, down 44% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -4607% | -1691 points |
| Q2 2026 | -5007% | -2605 points |
| Q1 2026 | -4835% | -4729 points |
| Q4 2025 | -3249% | -3234 points |
| Q3 2025 | -2915% | -2805 points |
| Q2 2025 | -2403% | -2459 points |
| Q1 2025 | -106% | -142 points |
| Q4 2024 | -16% | -27 points |
TRDA's operating margin was −4607% last quarter, down 1691 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over TRDA on cash generation, producing positive trailing cash flow while its opponent burns cash.
TRDA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$30.1M | -$2M |
| Q2 2026 | -$32.5M | -$2.7M |
| Q1 2026 | -$41.7M | -$2.1M |
| Q4 2025 | -$32M | +$244K |
| Q3 2025 | -$28.1M | -$3.2M |
| Q2 2025 | -$29.8M | -177% |
| Q1 2025 | -$39.7M | -$13.3M |
| Q4 2024 | -$32.2M | -$27.3M |
TRDA has burned cash in almost every quarter: −$136M over the past year, against −$130M the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over TRDA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
TRDA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +152K shares |
| 1 year | +2.2% | +911K shares |
| 3 years | +22% | +7.6M shares |
| 5 years | +107% | +21.9M shares |
TRDA has 42M diluted shares, up 2.2% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
TRDA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2025 | -8.7x | Net Cash |
| Q4 2024 | -2.0x | Net Cash |
| Q3 2024 | -1.3x | Net Cash |
| Q2 2024 | -1.9x | Net Cash |
| Q1 2024 | -2.5x | Net Cash |
TRDA has more cash than debt.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
TRDA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.2 | Neutral |
| Stochastic | 20.0 | Neutral |
TRDA's weekly RSI is 39 (neutral) and its Stochastic is 20 (neutral).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
TRDA PE vs Healthcare Sector
| Metric | TRDA | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
TRDA has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
TRDA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.07 | 2% above |
| 20 week MA | $6.22 | 17% below |
| 50 week MA | $8.73 | 41% below |
| 100 week MA | $8.84 | 42% below |
| 200 week MA | $11.9 | 57% below |
TRDA has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 57% below its 200-week average.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over TRDA on returns for 2026, with the stronger performance.
TRDA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $24.0 | $17.0 | -29% |
| 2022 | $17.0 | $15.0 | -12% |
| 2023 | $15.0 | $15.1 | +0.8% |
| 2024 | $15.1 | $17.4 | +15% |
| 2025 | $17.4 | $10.4 | -40% |
| 2026 YTD | $10.4 | $5.17 | -50% |
TRDA has finished lower in three of the last five years. It's down 50% so far in 2026.